Literature DB >> 6854379

Regional blood flow in RT-9 brain tumors.

R G Blasberg, P Molnar, M Horowitz, P Kornblith, R Pleasants, J Fenstermacher.   

Abstract

Regional blood flow (BF) was measured in RT-9 experimental brain tumors using carbon-14 labeled iodoantipyrine, the Kety tissue-exchange equations, and quantitative autoradiographic techniques. Blood flow was variable within tumor tissue, and the range of BF increased with increasing tumor size; the overall range was 6 to 138 ml/100 gm/min and the maximum range within an individual tumor was 55 ml/100 gm/min. In all but one case, mean tumor BF was less than that in the same anatomic region of the contralateral hemisphere (CBA). The magnitude of BF within individual tumor foci generally could be related to tumor size, location (intraparenchymal versus extraparenchymal), and the presence of necrosis or cysts; it was lower in the geometric centers than in the periphery of medium-sized and large tumors. Brain adjacent to tumor had higher BF's than the tumor periphery; generally, the BF in the brain adjacent to the tumor was less than that in the CBA. A global depression of BF was observed within tumor-free cortex and corpus callosum of the hemisphere ipsilateral to tumor implantation and primary growth, suggesting a hemispheric reduction in metabolic and functional activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6854379     DOI: 10.3171/jns.1983.58.6.0863

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  18 in total

1.  Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain.

Authors:  Hao-Li Liu; Mu-Yi Hua; Hung-Wei Yang; Chiung-Yin Huang; Po-Chun Chu; Jia-Shin Wu; I-Chou Tseng; Jiun-Jie Wang; Tzu-Chen Yen; Pin-Yuan Chen; Kuo-Chen Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-09       Impact factor: 11.205

Review 2.  Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.

Authors:  Arnold B Etame; Roberto J Diaz; Christian A Smith; Todd G Mainprize; Kullervo Hynynen; James T Rutka
Journal:  Neurosurg Focus       Date:  2012-01       Impact factor: 4.047

3.  Intracarotid recombinant human tumor necrosis factor-alpha reduces cerebral blood flow and methionine uptake in rat brain tumors.

Authors:  T Sasajima; K Mineura; M Kowada; J Hatazawa; S Miura
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

4.  Relationship between of blood flow, glucose metabolism, protein synthesis, glucose and ATP content in experimentally-induced glioma (RG1 2.2) of rat brain.

Authors:  G Mies; W Paschen; G Ebhardt; K A Hossmann
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

5.  Regional glucose utilization and blood flow in experimental brain tumors studied by double tracer autoradiography.

Authors:  A Kato; K Sako; M Diksic; Y L Yamamoto; W Feindel
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

Review 6.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Modification of tumor blood flow and enhancement of therapeutic effect of ACNU on experimental rat gliomas with angiotensin II.

Authors:  K Tokuda; H Abe; T Aida; S Sugimoto; S Kaneko
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

8.  Noisy intracranial tumours.

Authors:  B T van Dooren; A C van Bruggen; J J Mooij; J M Hew; H L Journée
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Murine sarcoma virus-induced brain tumors. Concurrent measurements of blood flow and transcapillary transport.

Authors:  F J Vriesendorp; D R Groothuis; N A Vick
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

10.  Growth of 9-L and RT-9 gliosarcoma in female rats.

Authors:  T Furuta; H A Wilkinson; T Fujiwara
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.